Adaptation Strategies for Coping With the Impact of Sensory Alterations on Eating Behavior in Children With Cancer: A Qualitative Study From the Perspective of Children and Parents (QUALISENS)

March 19, 2026 updated by: Centre Leon Berard

Childhood cancer is a serious and life-changing disease that affects thousands of children every year worldwide. In addition to the disease itself, cancer treatments such as chemotherapy often cause difficult side effects. Among these, changes in taste and smell are very common but still poorly understood in children. These sensory changes can make food taste unpleasant or smell different, leading children to eat less, avoid certain foods, or develop strong food aversions. As a result, many children with cancer experience weight loss, poor nutrition, and reduced quality of life, which can also affect how well they tolerate treatment.

Research suggests that between 40% and 60% of children with cancer struggle to maintain good nutritional status during treatment. Taste and smell alterations play a major role in these difficulties. Children may experience nausea triggered by food smells, changes in food texture perception, or a loss of pleasure in eating. Parents often report feeling powerless and lacking clear guidance on how to help their child cope with these problems.

While taste and smell disturbances have been widely studied in adults with cancer, much less is known about how children experience these changes and, importantly, how they and their families adapt to them. Parents play a key role in supporting their child's eating habits, but their perspectives may differ from the child's own experiences.

This study aims to better understand how children undergoing chemotherapy and their parents perceive changes in taste, smell, and food texture, and how these changes affect eating behavior, emotions, and social life. Using individual semi-structured interviews, the study will explore the coping strategies used by children and parents to manage these sensory changes, both at home and in the hospital setting.

By giving children and parents a voice, this research seeks to identify practical, real-life strategies that families find helpful. The results will contribute to improving nutritional support and guidance for children with cancer, with the ultimate goal of enhancing their well-being, quality of life, and treatment outcomes.

Study Overview

Detailed Description

Childhood cancer represents a major public health concern and remains one of the leading causes of disease-related mortality in children. Advances in treatment have improved survival, but chemotherapy is frequently associated with adverse effects that significantly impact nutritional status and quality of life. Malnutrition affects approximately 40-60% of pediatric oncology patients and is associated with poorer treatment tolerance, increased risk of infection, immune dysfunction, and reduced survival.

Among treatment-related toxicities, alterations in taste (dysgeusia) and smell (dysosmia) are increasingly recognized as key contributors to feeding difficulties. Chemotherapy targets rapidly dividing cells, including gustatory and olfactory receptor cells, which may explain the high prevalence of sensory disturbances. Taste and smell play a central role in appetite regulation and food enjoyment; their disruption can lead to reduced intake, food aversions, and changes in texture preferences. Although these effects are well documented in adults, pediatric data remain limited and heterogeneous, particularly regarding children's subjective experiences and coping mechanisms.

Recent studies suggest that up to 60% of children receiving chemotherapy experience taste and/or smell alterations perceived as highly distressing. Adolescents frequently report that food "does not taste good" and that food-related smells trigger nausea. Parents often identify sensory changes as the main cause of feeding problems, yet discrepancies may exist between parental perceptions and children's lived experiences. Furthermore, little is known about how food texture perception evolves in children with cancer, despite evidence that tactile oral sensitivity can strongly influence food selectivity.

This study is designed as a prospective, monocentric, non-interventional observational study (RIPH3), using a qualitative methodology based on individual semi-structured interviews. Participants will include children aged 6-17 years undergoing chemotherapy for a malignant hematological or solid tumor, and one of their parents or legal guardians. Interviews will be conducted separately with children and parents to ensure independent data collection and minimize mutual influence. Fifteen children and one of their parent will be included.

The primary objective is to identify and describe the coping strategies used by children and parents to manage taste, smell, and texture alterations and associated changes in eating behavior during chemotherapy. Secondary objectives include characterizing the nature, frequency, intensity, and duration of reported sensory alterations; exploring their emotional and social impact; examining the influence of cancer type, treatment stage, and eating context (hospital versus home); and assessing concordance and discrepancies between children's and parents' experiences and descriptions.

Data analysis will follow a rigorous qualitative approach, including thematic coding, verification of code saturation, and cross-checking by a second researcher to ensure analytical reliability. Reflexivity will be supported through the use of a field journal documenting the researcher's observations and potential biases.

This study will be among the first qualitative investigations in France to focus specifically on chemo-sensory alterations in pediatric oncology from both the child's and the parent's perspectives. By identifying effective, family-driven coping strategies, the findings aim to inform future nutritional guidance, supportive care interventions, and clinical recommendations, ultimately improving nutritional outcomes and quality of life for children undergoing cancer treatment.

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Lyon, France, 69008
        • Institut d'Hématologie et d'Oncologie Pédiatrique

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

History of cancer

Any cognitive impairment or condition that may limit the use of numerical scales and quality of life questionnaires, including but not limited to:

Children with neurodevelopmental disorders such as autism or Down syndrome These children may have specific cognitive or communication characteristics that require specialized interview techniques. Their inclusion could complicate data comparability and introduce confounding factors. This exclusion ensures data quality and consistency, while respecting the well-being of participants.

Patients for whom other types of cancer treatment are planned during the study period (e.g., radiation therapy) Patients in relapse Presence of a pre-existing pediatric eating disorder or pre-existing food selectivity

Description

Inclusion Criteria:

Children:

  • Aged 6 to 17 years old on the day consent is obtained.
  • Diagnosed with a malignant hematological or oncological tumor.
  • Possessing sufficient verbal ability to participate in the interview planned for the study.
  • Having started chemotherapy treatment at least 2 months prior.
  • Agreeing to participate in the study.
  • Able to understand, read, and write French.
  • Affiliated with a social security system.

Parents:

  • Be the parent or legal guardian of a child aged 6 to 17 inclusive, with cancer and undergoing chemotherapy.
  • Dated and signed informed consent.
  • Able to understand, read, and write French.

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
children aged 6-17 years undergoing chemotherapy for a malignant hematological or solid tumor
no intervention
one of the parent of the children included in the first group
no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
coping strategies of the children and their parents for managment of sensory alterations and eating behaviour
Time Frame: at least 2 months after the beginning of the chemotherapy

Determine the coping strategies used by children and their parents to manage sensory alterations and eating behavior during chemotherapy.

the method for the thematic analysis of qualitative data described by Braun and Clarke will be used

at least 2 months after the beginning of the chemotherapy

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Determine the effectiveness and purpose of these strategies.
Time Frame: at least 2 months after the beginning of the chemotherapy
the method for the thematic analysis of qualitative data described by Braun and Clarke will be used
at least 2 months after the beginning of the chemotherapy
Characterize the sensory alterations reported by children undergoing chemotherapy
Time Frame: at least 2 months after the beginning of the chemotherapy
the method for the thematic analysis of qualitative data described by Braun and Clarke will be used
at least 2 months after the beginning of the chemotherapy
Identify the frequency, reported intensity, and duration of alterations in taste, smell, and texture, and their role in eating behavior in children undergoing chemotherapy.
Time Frame: at least 2 months after the beginning of the chemotherapy
the method for the thematic analysis of qualitative data described by Braun and Clarke will be used
at least 2 months after the beginning of the chemotherapy
Determine the influence of cancer type and eating environment (hospital or home) on food perception
Time Frame: at least 2 months after the beginning of the chemotherapy
the method for the thematic analysis of qualitative data described by Braun and Clarke will be used
at least 2 months after the beginning of the chemotherapy
Study the impact of treatment type and stage on food perception and eating behavior.
Time Frame: at least 2 months after the beginning of the chemotherapy
the method for the thematic analysis of qualitative data described by Braun and Clarke will be used
at least 2 months after the beginning of the chemotherapy
Assess the role of sensory alterations on children's quality of life, particularly their emotional and social well-being.
Time Frame: at least 2 months after the beginning of the chemotherapy
the method for the thematic analysis of qualitative data described by Braun and Clarke will be used
at least 2 months after the beginning of the chemotherapy
Determine the relationship between the experiences of children and their parents by identifying their awareness of problems and their ability to describe them accurately.
Time Frame: at least 2 months after the beginning of the chemotherapy
the method for the thematic analysis of qualitative data described by Braun and Clarke will be used
at least 2 months after the beginning of the chemotherapy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Study Director: Anestis Dougkas, Institut Lyfe

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 1, 2026

Primary Completion (Estimated)

October 1, 2026

Study Completion (Estimated)

October 1, 2026

Study Registration Dates

First Submitted

February 9, 2026

First Submitted That Met QC Criteria

March 19, 2026

First Posted (Actual)

March 24, 2026

Study Record Updates

Last Update Posted (Actual)

March 24, 2026

Last Update Submitted That Met QC Criteria

March 19, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Smell Disorder

Clinical Trials on No Intervention: Observational Cohort

Subscribe